...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMJ: British medical journal >Bewacizumab for the treatment of neowascuiar age related macular degeneration Controversy remains about the off label use of bevacizumab
【24h】

Bewacizumab for the treatment of neowascuiar age related macular degeneration Controversy remains about the off label use of bevacizumab

机译：Bewacizumab neowascuiar时代的治疗黄斑变性的争议仍然存在关于标签使用贝伐单抗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The era of biological agents for the management of neo-vascular age related macular degeneration was firmly ushered in when two randomised controlled clinical trials in 2007 found that ranibizumab, a monoclonal antibody to vascular endothelial growth factor, improved visual outcomes in patients with this condition.12 However even before the original trial data were released, ophthalmologists had already begun to treat patients with neovascular age related macular degeneration with bevacizumab (the parent molecule of ranibizumab), which is licensed for intravenous administration in advanced colorectal cancer. In the linked study, Tufail and colleagues report their findings from the ABC Trial, a multicentre randomised controlled study that compared the use of bevacizumab and ranibizumab for the treatment of neovascular (wet) age related macular degeneration.
机译：生物制剂管理的时代neo-vascular年龄相关黄斑变性坚定地迎来了两个随机对照临床试验发现之初,2007年血管内皮的单克隆抗体生长因子,改善视觉效果这个患者condition.12在最初的试验数据公布之前,眼科医生已经开始治疗新生血管性患者与年龄相关的黄斑变性与贝伐单抗(父分子之初)许可在先进的结直肠静脉政府癌症。从美国广播公司的同事们将研究成果发表试验中,一个多中心随机对照研究比较了使用贝伐单抗和为治疗新生血管性之初(湿)年龄相关黄斑变性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号